Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Huntsville, AlabamaAges 18 years+ - NCT06712823RecruitingPhase 2
Long-term safety study of atumelnant for adrenal hyperplasia
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
Minneapolis, MinnesotaAges 16–74 - NCT06716138RecruitingPhase 1
ANS03 for solid tumors with ROS1 or NTRK changes
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT06709040Enrolling by invitation
Long-term safety of somapacitan in children with growth hormone deficiency
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
Glasgow, ScotlandAges Up to 18 years - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85 - NCT06696534Recruiting
Patient views on colorectal cancer screening methods
This study asks people aged 50–69 about their experience and preferences with different screening methods for colorectal cancer. It aims to improve screening programs by understanding what patients prefer.
LisbonAges 50–69 - NCT06701201Enrolling by invitation
Long-term follow-up for SynKIR CAR T cell patients
This study monitors participants who have received a SynKIR CAR T cell treatment in a past Verismo Therapeutics trial. It aims to track long-term health and safety outcomes over time.
Denver, ColoradoAges 18 years+ - NCT06694480RecruitingPhase 1
Study of FID-022 for advanced solid tumors
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Duarte, CaliforniaAges 18 years+ - NCT06697197RecruitingPhase 1/Phase 2
Study of experimental drug BMS-986482 for advanced solid tumors
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
Irvine, CaliforniaAges 18 years+ - NCT06696755RecruitingPhase 2
Study of icalcaprant for bipolar depression
This study tests an oral medication called icalcaprant for adults with bipolar I or II who are currently in a depressive episode. The goal is to see if it reduces symptoms and whether it's safe when taken alongside your usual mood stabilizer.
Huntsville, AlabamaAges 18–65 - NCT06697184RecruitingPhase 1/Phase 2
Testing a slower start of sonrotoclax for blood cancers
This trial tests a new way to slowly increase the dose of the drug sonrotoclax when starting treatment for blood cancers like chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). The goal is to see if this slower start is safer and better tolerated.
Tampa, FloridaAges 18 years+ - NCT06704672Recruiting
Effect of a new glucose sensor on blood sugar control in diabetes
This study compares a continuous glucose monitor (CGM) to fingerstick testing for people with type 1 or type 2 diabetes who give themselves insulin injections. It aims to see if using the sensor helps increase the time blood sugar stays in a healthy range.
GdanskAges 18 years+ - NCT06704048Recruiting
Heart rehab after endocarditis: quality of life study
This study looks at how a heart rehabilitation program affects quality of life and personal experiences in people who have been treated for infective endocarditis (a serious heart infection). It aims to find out if this type of rehab helps patients feel better and recover more fully.
Halmstad, Halland CountyAges 18–90 - NCT06686576RecruitingPhase 3
Study of QL1706 before surgery for MSI-H colon cancer
This trial tests a new immunotherapy medicine (QL1706) given before surgery to treat colon cancer that hasn't spread yet. It's designed for patients whose tumors have a specific gene feature (MSI-H/dMMR) and who haven't had any prior treatment for this cancer.
GuangzhouAges 18–75 - NCT06682975RecruitingPhase 1
Safety study of ZP9830 in healthy people
This study tests a new medicine called ZP9830 to see if it is safe for people and how it works in the body. Healthy volunteers aged 18 to 45 can join.
Leiden, CLAges 18–45 - NCT06682988RecruitingPhase 2
New treatment for advanced ovarian cancer
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Sarasota, FloridaAges 18 years+ - NCT06685536Enrolling by invitation
Long-term follow-up for CS-101 recipients
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
Nanning, GuangxiAges 6–35 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06686394RecruitingPhase 1/Phase 2
Patritumab deruxtecan combinations for advanced HER2-positive breast cancer
This trial tests a new drug, patritumab deruxtecan, combined with other anti-cancer drugs for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if these combinations can shrink tumors or slow cancer growth.
Aurora, ColoradoAges 18 years+ - NCT06672549RecruitingPhase 3
Weight loss medication study for children with obesity
This trial tests a medication for children and teens with obesity or overweight who have not been able to lose enough weight with diet and exercise alone. It aims to see if a new treatment can help them safely lose weight and improve related health problems.
Tucson, ArizonaAges 6–17 - NCT06672523RecruitingPhase 1
Study of a new drug for advanced solid tumors with MTAP deletion
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
BudapestAges 18 years+ - NCT06678659RecruitingPhase 1/Phase 2
Study of REC-1245 for advanced solid tumors and lymphoma
This trial tests a new drug, REC-1245, for people with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow disease progression.
Duarte, CaliforniaAges 12 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06680037RecruitingPhase 1
Azer-cel therapy for immune-related neurological diseases
This trial is testing an experimental cell therapy called azer-cel for people with certain autoimmune diseases that affect the nervous system. The therapy aims to reduce immune attacks on the body by targeting and removing faulty B cells.
La Jolla, CaliforniaAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.